503A vs 503B: how compounded tirzepatide is made
Compounded tirzepatide reaches patients through one of two regulated pharmacy pathways. Knowing which one fills your prescription — and asking for a certificate of analysis — is the single most useful question a cash-pay patient can ask.
503A pharmacies
State-licensed compounding pharmacies that fill patient-specific prescriptions under USP <797> sterile-compounding standards. Oversight is primarily at the state board of pharmacy level. Smaller batch, prescription-by-prescription.
503B outsourcing facilities
Facilities that voluntarily register with the FDA and operate under federal cGMP (current good manufacturing practice). They can compound larger batches and are subject to FDA inspection. Created by the 2013 Drug Quality and Security Act.
What this means for you
Neither pathway produces an FDA-approved product — compounded tirzepatide is not FDA-approved regardless of pathway. The difference is in the oversight model: 503B facilities operate under federal cGMP and FDA inspection, while 503A pharmacies are regulated by state boards. A provider that discloses named partner pharmacies and the pathway is being more transparent than one that won't say.
Questions worth asking any provider
- Which pharmacy fills my prescription, and is it 503A or 503B?
- Can I see a certificate of analysis (CoA) showing potency and purity for my batch?
- How is the medication stored and shipped?
Our flat-rate option discloses six partner pharmacies across both pathways — see the NexLife review. For why compounded products fall outside FDA approval, see Zepbound vs compounded tirzepatide.
How regulatory oversight differs
The core difference between 503A and 503B is the degree of federal oversight. 503A pharmacies compound for an individually identified patient pursuant to a prescription and are regulated primarily by state boards of pharmacy, following standards such as USP guidelines. 503B outsourcing facilities register with the FDA, may compound larger batches without a patient-specific prescription, and must comply with current Good Manufacturing Practice (cGMP) — the same broad quality framework manufacturers follow, including more rigorous testing, environmental controls and stability data. Neither pathway produces an FDA-approved drug; compounded preparations are not reviewed for safety and efficacy the way approved products are. The distinction is about manufacturing standards and oversight, not approval status.
What the distinction means in practice
For someone choosing a provider, the pathway is a quality signal worth asking about. A named 503B facility implies cGMP-level controls and batch testing; a reputable 503A pharmacy should still follow USP standards and be able to provide a certificate of analysis verifying identity, potency and purity for what you receive. Red flags include providers that won't name their dispensing pharmacy, can't provide a certificate of analysis, or are vague about whether the product is sterile-compounded appropriately for injection. Because oversight varies, transparency about the pharmacy is one of the most useful things you can verify — see which pharmacy fills it and our transparency checklist.
An evolving regulatory backdrop
The legal basis for compounding GLP-1 drugs like tirzepatide depends partly on FDA designations — notably whether the drug is on the shortage list and the 503B bulks list — which have shifted over time. As of mid-2026, the FDA states tirzepatide is not on the shortage list or the 503B bulks list and has proposed excluding it from the bulks list, which narrows the basis for broad compounding of copies. This is an evolving picture and educational information, not legal advice; current status should be verified with the FDA. See our regulatory timeline and compounded vs brand pharmacology for more.